The Latest Breaking News from Merck

It's only November — but if you're like most investors — 2024 is what matters now. And some S&P 500 companies already look primed to put up big numbers.

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

Merck's Keytruda continued to pull its weight in the third quarter, helping deliver a beat and raise that could stoked Merck shares.

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Almost 68% of patients responded to an experimental bladder cancer treatment from Merck and Seagen. Merck stock jumped Monday.

The Dow Jones fell sharply with the other major stock indexes ahead of a busy week of high-profile earnings reports in the tech sector.

Dow Jones industrials, such as Nike, have pulled back significantly amid recent market turmoil, and now trade at a steep discount to consensus price target estimates.

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.